Literature DB >> 10484479

EEG and ocular correlates of circadian melatonin phase and human performance decrements during sleep loss.

C Cajochen1, S B Khalsa, J K Wyatt, C A Czeisler, D J Dijk.   

Abstract

The aim of this study was to quantify the associations between slow eye movements (SEMs), eye blink rate, waking electroencephalogram (EEG) power density, neurobehavioral performance, and the circadian rhythm of plasma melatonin in a cohort of 10 healthy men during up to 32 h of sustained wakefulness. The time course of neurobehavioral performance was characterized by fairly stable levels throughout the first 16 h of wakefulness followed by deterioration during the phase of melatonin secretion. This deterioration was closely associated with an increase in SEMs. Frontal low-frequency EEG activity (1-7 Hz) exhibited a prominent increase with time awake and little circadian modulation. EEG alpha activity exhibited circadian modulation. The dynamics of SEMs and EEG activity were phase locked to changes in neurobehavioral performance and lagged the plasma melatonin rhythm. The data indicate that frontal areas of the brain are more susceptible to sleep loss than occipital areas. Frontal EEG activity and ocular parameters may be used to monitor and predict changes in neurobehavioral performance associated with sleep loss and circadian misalignment.

Entities:  

Keywords:  NASA Discipline Regulatory Physiology; Non-NASA Center

Mesh:

Substances:

Year:  1999        PMID: 10484479     DOI: 10.1152/ajpregu.1999.277.3.r640

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  86 in total

1.  The homeostatic regulation of sleep need is under genetic control.

Authors:  P Franken; D Chollet; M Tafti
Journal:  J Neurosci       Date:  2001-04-15       Impact factor: 6.167

2.  Does sleep restore the topology of functional brain networks?

Authors:  Maria M G Koenis; Nico Romeijn; Giovanni Piantoni; Ilse Verweij; Ysbrand D Van der Werf; Eus J W Van Someren; Cornelis J Stam
Journal:  Hum Brain Mapp       Date:  2011-11-11       Impact factor: 5.038

3.  Polymorphisms of ADORA2A modulate psychomotor vigilance and the effects of caffeine on neurobehavioural performance and sleep EEG after sleep deprivation.

Authors:  S Bodenmann; C Hohoff; C Freitag; J Deckert; J V Rétey; V Bachmann; H-P Landolt
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

4.  Uncovering residual effects of chronic sleep loss on human performance.

Authors:  Daniel A Cohen; Wei Wang; James K Wyatt; Richard E Kronauer; Derk-Jan Dijk; Charles A Czeisler; Elizabeth B Klerman
Journal:  Sci Transl Med       Date:  2010-01-13       Impact factor: 17.956

5.  Sleep Loss and Fatigue in Shift Work and Shift Work Disorder.

Authors:  Torbjörn Akerstedt; Kenneth P Wright
Journal:  Sleep Med Clin       Date:  2009-06-01

6.  High risk of near-crash driving events following night-shift work.

Authors:  Michael L Lee; Mark E Howard; William J Horrey; Yulan Liang; Clare Anderson; Michael S Shreeve; Conor S O'Brien; Charles A Czeisler
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-22       Impact factor: 11.205

7.  The transcription factor DBP affects circadian sleep consolidation and rhythmic EEG activity.

Authors:  P Franken; L Lopez-Molina; L Marcacci; U Schibler; M Tafti
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

8.  Assessment of drowsiness based on ocular parameters detected by infrared reflectance oculography.

Authors:  Clare Anderson; Anne-Marie Chang; Jason P Sullivan; Joseph M Ronda; Charles A Czeisler
Journal:  J Clin Sleep Med       Date:  2013-09-15       Impact factor: 4.062

9.  PVT lapses differ according to eyes open, closed, or looking away.

Authors:  Clare Anderson; Alan W J Wales; James A Horne
Journal:  Sleep       Date:  2010-02       Impact factor: 5.849

Review 10.  The impact of housestaff fatigue on occupational and patient safety.

Authors:  Scot A Mountain; Bradley S Quon; Peter Dodek; Robert Sharpe; Najib T Ayas
Journal:  Lung       Date:  2007-05-03       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.